Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5464353 | 0.85 | MAPT (0.59) | MEN1KMT2AMAPTHRH3 | |
| SCHEMBL2953452 | 0.85 | ALDH1A1 (0.77) | ALDH1A1GAAMEN1KMT2AALOX15 | |
| SCHEMBL5457457 | 0.84 | ROCK2 (0.50) | MEN1KMT2AMAPTHTTSMN1; SMN2 | |
| SCHEMBL5464035 | 0.83 | ALDH1A1 (0.61) | ALDH1A1MEN1KMT2AMAPTMAPK1 | |
| SCHEMBL5464323 | 0.82 | HRH3 (0.51) | ALDH1A1MEN1KMT2AMAPTTSHR | |
| SCHEMBL5461526 | 0.82 | HRH3 (0.55) | ALDH1A1MAPTHRH3 | |
| SCHEMBL5451040 | 0.81 | HRH3 (0.49) | MEN1KMT2AMAPTSMN1; SMN2HRH3 | |
| SCHEMBL5463884 | 0.80 | HRH3 (0.55) | MAPTHRH3 | |
| SCHEMBL5458837 | 0.79 | KMT2A (0.53) | ALDH1A1MEN1KMT2AALOX15MAPT | |
| SCHEMBL5458846 | 0.79 | HRH3 (0.74) | ALDH1A1GAAMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | CNR2, GRIN2C, GRIN2B | ALDH1A1 1805/4885GAA 1910/4885MEN1 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.